Based on serology, immunohistochemistry, and imaging, studies targeting genetic abnormalities such as IDH1/2, FGFR2, and BRAF have improved ICC diagnosis accuracy and achieved precise targeted treatment,[35,36] supporting the improvement of LT efficacy. This evidence concerns the gene BRAF and intrahepatic cholangiocarcinoma.